Abstract 6845: Evaluation of individual drug response to tyrosine kinase inhibitor treatment in precision-cut tumor slices of gastrointestinal stroma tumors
Dina Mönch(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), J. Koch(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Philipp Renner(Robert Bosch Hospital), Annette M. Staiger(Robert Bosch Hospital), Thomas E. Mürdter(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Matthias Schwab(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Tobias Leibold(Robert Bosch Hospital), German Ott(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Julia Thiel(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Marc‐Hendrik Dahlke(Robert Bosch Hospital), Katrin S. Kurz(Robert Bosch Hospital), Meng Dong(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Annika Maaß(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology)
Cited by 0
Related Papers
A roadmap for graphene
|Nature|2012|9.1k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k